AGAP3

Across TCGA pan-cancer cohorts, AGAP3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AGAP3 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher AGAP3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AGAP3 expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

LUAD, GBM, and LSCC are the cancer types where AGAP3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.639	0.960	.005	10	view →
GBM	DFS	Quartile	All	0.924	0.690	.006	5	view →
LSCC	OS	Median	All	0.715	1.000	.002	5	view →
HNSC	DFS	Median	IV	0.889	0.407	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

AGAP3–LUAD (DFS)

Open the LUAD breakdown →